The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...
Marks offered his resignation while citing Kennedy’s “misinformation and lies” and an “unprecedented assault on scientific ...
Vaccine makers were hit particularly hard yesterday, as Marks’ resignation letter alluded to disagreements with HHS Secretary ...
Biotech stocks took a hit after the sudden resignation of Dr. Peter Marks, head of the FDA’s Center for Biologics Evaluation ...
As the FDA’s top biologics official, Peter Marks oversaw regulation of cell and gene therapies. The departure of Marks and mass layoffs throughout the FDA raise concerns about the agency’s ability to ...
The U.S. Food and Drug Administration said on Tuesday it had named Scott Steele as acting director of its Center for ...
As the FDA wavers from cuts, changes and departures under the second Trump administration, another vital figure of the agency ...
Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.
The stock market—and biotech insiders—reacted negatively to the allegedly forced resignation of CBER Director Peter Marks, ...